Login to Your Account



Genable deal taps into Spark’s gene therapy expertise

By Cormac Sheridan
Staff Writer

Tuesday, March 25, 2014
DUBLIN – Genable Technologies Ltd. is dipping into Philadelphia’s deep pool of gene therapy expertise by entering a collaboration agreement with Spark Therapeutics LLC, under which the latter firm will provide manufacturing services and clinical development assistance on its lead program, GT038, currently in preclinical development for rhodopsin-linked autosomal dominant retinitis pigmentosa (RP).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription